What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract?
Carola A.S. Arndt(Mayo Clinic in Florida), William M. Crist(St. Jude Children's Research Hospital), James R. Anderson(Merck & Co., Inc., Rahway, NJ, USA (United States)), R. Beverly Raney(The University of Texas MD Anderson Cancer Center), Fran Laurie(University of Massachusetts Chan Medical School), Harold M. Maurer(University of Nebraska Medical Center), Michael P. Link(Stanford University), Richard J. Andrassy(The University of Texas MD Anderson Cancer Center), Sarah S. Donaldson(Stanford University)
Cited by 139
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|920
Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors
|Cancer Discovery|2014|789
Long-Term Outcomes Among Adult Survivors of Childhood Central Nervous System Malignancies in the Childhood Cancer Survivor Study
|JNCI Journal of the National Cancer Institute|2009|530
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
|Journal of Clinical Oncology|2017|485